| Methods |
Inclusion criteria= sitting DBP 90‐105 mm Hg before start of study; 3‐week double‐blind treatment |
| Participants |
Cilazapril 2.5 mg: n=14(11 males,3 females); mean age=63.7(4.2) years; baseline SBP=139 mm Hg, DBP=92 mm Hg;
Placebo: n=12(10 males,2 females); mean age=63.3(7.8) years; baseline SBP=135 mm Hg, DBP=92 mm Hg |
| Interventions |
Cilazapril 2.5 mg once daily;
Placebo;
administered in the morning before breakfast |
| Outcomes |
Peak (2‐3 h after dosing) supine SBP/DBP using mercury sphygmomanometer;
Peak (2‐3 h after dosing) HR;
WDAE |
| Notes |
Used DBP only since patients did not have SBP >/= 140 mm Hg at baseline; BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from text, p. 446; Jadad score=3; funding source= Hoffman‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
